Four things academic researchers assume about biotech grants that aren't quite right.
The transition from academic to biotech grant writing surfaces the same misconceptions reliably enough that they're worth addressing directly.
Here are the four I see most often.
Myth 1: Strong science is enough to get funded.
Strong science is necessary. It is not sufficient. SBIR and STTR exist to move research toward commercialization, and reviewers are evaluating your application through that lens whether you've written to it or not. A technically excellent application that doesn't address the commercial pathway, the market, and the real-world feasibility of the product will consistently score below its scientific merit.
Myth 2: The commercialization plan is like the broader impacts section.
It isn't. Broader impacts in an NSF application or the significance section in an NIH application are important, but they are not scored with the same weight as the scientific content. The SBIR commercialization plan is a fully scored section that reviewers read carefully and comment on specifically. Vague language about broad clinical potential and licensing opportunities will not cut it. Reviewers want customer segments, competitive landscape, regulatory pathway, and a credible line of sight from your Phase I results to a product.
Myth 3: Preliminary data just needs to show the science works.
In an academic grant, preliminary data exists to demonstrate that your hypothesis is plausible and your approach is feasible. In a biotech grant, it needs to do that and signal something more: that the technology holds up outside a controlled research environment, that it could work at scale, that it has the characteristics of something a market would eventually pay for. The bar is not just scientific promise. It is translational credibility.
Myth 4: A great PI record speaks for itself.
Publication record and grant history matter in SBIR and STTR applications. But reviewers are also looking for evidence that someone on the team understands how to move something from research to product. If your team is entirely academic with no operational or commercial experience, that gap is worth addressing directly in the application rather than leaving reviewers to wonder about it.
Moving from academic to biotech grants?
If you're used to writing for academic reviewers, the shift to SBIR or STTR can require more than adapting your language. The reviewers are evaluating different things, and what worked in an academic application may not be enough here. Let's talk through your application and make sure you're addressing what biotech reviewers actually need to see.
Comments